A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older adults long-term protection against the infection, even if efficacy wanes ...

GSK's (GSK) stock rises as the company's Arexvy shot could see expanded CDC recommendations for RSV protection in at-risk ...

Pfizer Inc. has announced the company has discontinued the development of danuglipron (PF-06882961), an oral glucagon-like ...

As millions of Brits battle runny noses, croaky coughs and watery eyes, it may be easy to chug an antihistamine, but the nation is also known for a series of common viruses this time of year.

In 2024, administration of the four FDA-approved RSV vaccinations was low, ranging from 0.27% to 0.58%, according to a poster ...

GlaxoSmithKline (GSK) and Pfizer filed a stipulation to dismiss with prejudice GSK’s litigation in the United States District ...

Laboratory-confirmed and diagnosed COVID-19 cases and COVID-19 outbreaks must still be reported to the Vermont Department of ...

Pfizer and GlaxoSmithKline have agreed to end a lawsuit over alleged patent infringement involving their competing ...

Acute respiratory syncytial virus was associated with elevated incidence of cardiovascular events among older adults, ...

In recent developments, a class action lawsuit was filed against Cerevel Therapeutics, Bain Capital Investors, and Pfizer ...

GSK and Pfiz­er have set­tled a law­suit al­leg­ing Pfiz­er’s RSV shot Abrys­vo in­fringed GSK’s patents. A Pfiz­er ...

GSK Plc and Pfizer Inc. settled a patent-infringement lawsuit over competing vaccines for RSV, ending the dispute in Delaware ...